Neha Lad (@nehalad798) header
Neha Lad (@nehalad798) profile picture

Surgical history enthusiast, love hiking, an aberrant HPB, transplant & surg onc trained, now @MtSinaiSurgOnc @MSHSSurgery

Joined November 2013
Photo by Neha Lad (@nehalad798)Photo by Neha Lad (@nehalad798)Photo by Neha Lad (@nehalad798)Photo by Neha Lad (@nehalad798)Photo by Neha Lad (@nehalad798)Photo by Neha Lad (@nehalad798)Photo by Neha Lad (@nehalad798)Photo by Neha Lad (@nehalad798)Photo by Neha Lad (@nehalad798)Photo by Neha Lad (@nehalad798)
Delighted to be a part of this effort with global 🌎 colleagues to help update the guidelines of carcinoid crisis management championed by Dr. Rod Pommier @OHSUKnight @NANETS1
What to do with carcinoid crisis in NET surgery? 🆕 Consensus guidance out @BJSOpen 44 experts 🌏18 countries ❌ No routine octreotide prophylaxis ⬆️ Vasopressors as 1st line 🔑 Preop: screen for carcinoid syndrome & heart doi.org/10.1093/bjsopen/zrag… @spartelli @DrFadiTO
1
2
8
791
In 2,760 patients undergoing pancreatic cancer resection, factors predicting overall survival differed by receipt of neoadjuvant therapy, highlighting the need for treatment-specific prognostic models. ovid.com/10.1097/SLA.0000000…
1
6
22
2,950
Important to act on all mesenteric mass in SB-NET 👥 73 resected SiNETs ⏳ OS and PFS similar <2 vs ≥2 cm ⚖️ Long survival either way, but bulky mesenteric disease costs QoL 🔑 Detect early & operate before it grows journals.sagepub.com/doi/10.…
🤖 Made with AI
10
32
1,686
In a single-institution study of distal pancreatectomy, surgical drain placement was not associated with the development of postoperative fluid collections but was associated with a higher rate of clinically relevant postoperative pancreatic fistula. ovid.com/10.1097/SLA.0000000…
3
13
1
27
5,322
In a single-institution study after distal pancreatectomy, fluid collections developed in 53% of patients, but only approximately one fourth were associated with clinically relevant postoperative pancreatic fistula. ovid.com/10.1097/SLA.0000000…
2
15
1
60
7,530
Replying to @Schwaitzberg
@Schwaitzberg ACS Congress was extra special this year as we got to celebrate our beloved chair Dr. Steven Schwaitzberg. While some of us were fortunate to be there in person many more sent their messages in letters which we compiled into a book “Hands trained lives changed”
2
3
116
Don't miss out! This webinar will bring together experts from Mexico, Brazil, the United States, and other countries across the Americas to examine current controversies and opportunities to improve multidisciplinary gallbladder cancer care. Register: ow.ly/66km50ZGHCF
7
1
14
2,080
In pancreatic cancer with synchronous liver metastases, “technically removable” is not the same as “biologically worth operating on.” Systemic therapy may be the most informative stress test. A retrospective cohort from colleagues at China-Japan Friendship Hospital included 69 consecutive patients; 52 received at least four cycles of systemic therapy and were evaluable for response. The strongest prognostic signal was concordance: radiographic partial response plus CA19-9 falling by more than 85% or normalizing. Median overall survival was 49 months in dual responders versus 11 months in patients with one or neither response. Among patients whose primary tumor was initially resectable or borderline resectable, the apparent surgical signal was concentrated in those dual responders. Patients without that concordant response did not show a survival difference associated with resection (11 vs 12 months). My read: this does not make surgery standard for stage IV pancreatic cancer. It suggests a better selection question: after adequate systemic therapy, do imaging and tumor-marker kinetics tell the same story of unusually favorable biology? A removable liver lesion or a falling CA19-9 alone is not enough. The study is retrospective and highly selected, so treatment selection and survivor bias can produce part of the observed difference. The dual-response rule needs prospective validation before it can define who benefits from surgery. Wei R, et al. HepatoBiliary Surgery and Nutrition. 2026. DOI: 10.21037/hbsn-2025-289
2
3
187
Autologous peritoneal patch for venous reconstruction: A systematic review of clinical outcomes 🌷doi.org/10.14701/ahbps.26-12… Ann Hepatobiliary Pancreat Surg 2026;30(3). Abdallah Al Farai #Peritoneum #Veins #GeneralSurgery
9
22
1,024
Gallbladder polyp management isn’t just size-based. European vs SRU guidelines differ on size, morphology, risk & follow-up. Some polyps may be malignant, surgical planning matters. Do you use European, SRU, or individualized approach? When consider extended cholecystectomy?
🤖 Made with AI
5
91
247
10,534
📢Louder for the people in the back: PanNET is not PDAC Major postop risk differences 👥4152 whipple 🇳🇱 ⚠️PanNET major complications⬆️x3 vs other indications 🔑Generic postop data can't define PanNETs risk–benefit Tailor decisions to biology and risks tinyurl.com/ycyjcjmr
🤖 Made with AI
12
1
38
2,476
Is this the World Cup 🏆 for PDAC studies?! 💉 First in human #Kras vaccine for PDAC interception in high risk cohort 😱 👮 T Cell response in 90% persisting up to 2 years - no participants developed PDAC 🍿 and now we can enjoy 🇪🇸 🇦🇷 … 😜 aacrjournals.org/cancerdisco…
13
1
48
3,877
What do we mean with "recurrence" of IPMN 🍇 after surgery ?! ☝️ word - ✌️ different scenario 🆕 IPMN after resection of non-invasive are "de novo" in 50% cases 🦀 Recurrence of invasive IPMN was 42%, most systemic if 🍒 node + and tubular type academic.oup.com/bjsopen/art…
18
1
54
4,014
#AudioVisualAbstract : Laparoscopic Management of Suspected #GallbladderCancer : Risk Stratified Approach in Thick-Walled Gallbladder and Polyps ow.ly/8g5M50ZiNtc @NabeelZafarMD @SyedAAhmad5
1
12
18
1,751
Have you ever wondered what the outcomes are of patients with small bowel NETs and liver mets following cytoreductive hepatectomy if there is co-existing carcinoid heart disease (CHD)? Are the outcomes different in the CHD population when compared to those without CHD? As it seems, probably not. In this retrospective study done at Mayo Clinic, the outcomes of 311 patients were analyzed. 163 had nonfunctional NETs, 110 had carcinoid syndrome (CS) and 38 had CS + CHD. Median overall survival after debulking was very similar, 12.5 vs. 9.1 vs 11.4 years. With optimal cardiac management, cytoreductive hepatectomy in CHD is feasible and provides long-term survival comparable to patients without CHD. Careful multidisciplinary evaluation and management is key. onlinelibrary.wiley.com/doi/… @MayoCancerCare @MayoClinicSurg
1
6
24
1,627
Neha Lad retweeted
Underwood et al. found robotic pancreatoduodenectomy increased 1.1% to 10.3% of pancreatic cancer resections in the US between 2010–2020. Outcomes best at high-volume centres reinforcing value of centralisation & structured training as RPD adoption grows 🔗tinyurl.com/2fr34vc3
8
1
14
2,296